NVX-CoV2373 vaccine is filed for Emergency Use Authorization to prevent COVID 19 in Taiwan. Novavax
Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization against SARS-CoV-2 in individuals aged 18 and over.
The submission includes data from two pivotal Phase III clinical trials: PREVENT-19, which enrolled approximately 30,000 participants aged 18 years and older in the U.S. and Mexico and was published in the New England Journal of Medicine (NEJM) (previously cited); and a UK-based trial with almost 15,000 adult participants, also published in NEJM. In both trials, the vaccine demonstrated efficacy with a reassuring safety profile.
See also: "Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine"; P.T. Heath and Others.February 10, 2022. N Engl J Med 2022; 386:531-543.